Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron to $1,182 from $1,183 and keeps an Overweight rating on the shares. For Q2, the firm model’s Eylea U.S. sales of $1.57B, versus consensus at $1.47B, and is in line with Dupixent consensus sales estimates at $3.45B, the analyst tells investors in an earnings preview note for the Biopharma group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $1,200 from $1,050 at Barclays
- Regeneron, Sanofi announce EC approval for Dupixent
- Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
- Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Regeneron announces positive CHMP opinion for odronextamab